Cancer Causes & Control

, Volume 24, Issue 1, pp 167–174 | Cite as

The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans

  • Jonathan N. Hofmann
  • Kendra Schwartz
  • Wong-Ho Chow
  • Julie J. Ruterbusch
  • Brian M. Shuch
  • Sara Karami
  • Nathaniel Rothman
  • Sholom Wacholder
  • Barry I. Graubard
  • Joanne S. Colt
  • Mark P. Purdue
Original paper

Abstract

Purpose

In the United States, renal cell carcinoma (RCC) incidence is higher among blacks than among whites. Risk of RCC is elevated among end-stage renal disease patients, although no studies have looked at differences by race in the relationship between chronic renal failure and RCC.

Methods

We investigated RCC risk in relation to chronic renal failure in a population-based case–control study of blacks and whites in Chicago and Detroit. Data, including information on kidney disease, were collected from interviews with 1,217 RCC cases (361 blacks, 856 whites) and 1,235 controls (523 blacks, 712 whites). Odds ratios (OR) and 95 % confidence intervals (CI) were estimated using unconditional logistic regression.

Results

Risk of RCC was increased in relation to chronic renal failure (OR 4.7, 95 % CI 2.2–10.1) and dialysis (OR 18.0, 95 % CI 3.6–91). The association remained after defining exposure as those who had chronic renal failure ≥10 years prior to RCC diagnosis. Chronic renal failure was more strongly associated with RCC among blacks than among whites (OR 8.7, 95 % CI 3.3–22.9 and 2.0, 0.7–5.6, respectively; pinteraction = 0.03) and among those without a history of diabetes relative to diabetic subjects (OR 8.3, 95 % CI 3.1–22.7 and 1.9, 0.6–5.9, respectively; pinteraction = 0.03).

Conclusions

These results suggest that chronic renal failure is a strong risk factor for RCC, particularly among black and non-diabetic subjects. Our findings of differences in risk estimates by race, to our knowledge the first such report, require replication.

Keywords

Renal cell carcinoma Kidney cancer Chronic renal failure End-stage renal disease Racial disparities 

References

  1. 1.
    Chow WH, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7:245–257PubMedCrossRefGoogle Scholar
  2. 2.
    Chow WH, Devesa SS (2008) Contemporary epidemiology of renal cell cancer. Cancer J 14:288–301PubMedCrossRefGoogle Scholar
  3. 3.
    Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL et al (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:1891–1901PubMedCrossRefGoogle Scholar
  4. 4.
    Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14:197–207PubMedCrossRefGoogle Scholar
  6. 6.
    Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR (2009) The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 24:3225–3231PubMedCrossRefGoogle Scholar
  7. 7.
    Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE (2006) Cancer incidence before and after kidney transplantation. JAMA 296:2823–2831PubMedCrossRefGoogle Scholar
  8. 8.
    United States Renal Data System (2011) USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, BethesdaGoogle Scholar
  9. 9.
    Martins D, Tareen N, Norris KC (2002) The epidemiology of end-stage renal disease among African Americans. Am J Med Sci 323:65–71PubMedCrossRefGoogle Scholar
  10. 10.
    Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, Digaetano R, Purdue M, Rothman N, Wacholder S, Chow WH (2011) Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 22:797–804PubMedGoogle Scholar
  11. 11.
    Rust KF, Rao JN (1996) Variance estimation for complex surveys using replication techniques. Stat Methods Med Res 5:283–310PubMedCrossRefGoogle Scholar
  12. 12.
    McClellan W, Tuttle E, Issa A (1988) Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 12:285–290PubMedGoogle Scholar
  13. 13.
    Klein JB, Nguyen CT, Saffore L, Modlin C III, Modlin CS Jr (2010) Racial disparities in urologic health care. J Natl Med Assoc 102:108–117PubMedGoogle Scholar
  14. 14.
    Weng FL, Joffe MM, Feldman HI, Mange KC (2005) Rates of completion of the medical evaluation for renal transplantation. Am J Kidney Dis 46:734–745PubMedCrossRefGoogle Scholar
  15. 15.
    Lipworth L, Tarone RE, McLaughlin JK (2011) Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer 11:133PubMedCrossRefGoogle Scholar
  16. 16.
    Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ et al (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841–845PubMedCrossRefGoogle Scholar
  17. 17.
    Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL et al (2011) APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22:2129–2137PubMedCrossRefGoogle Scholar
  18. 18.
    Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J et al (2011) APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22:1991–1996PubMedCrossRefGoogle Scholar
  19. 19.
    Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, Pandey B, Schork NJ, O’Connor DT (2011) Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American study of kidney disease and hypertension (AASK) trial and veterans affairs hypertension cohort (VAHC). Nephrol Dial Transplant 27:197–205PubMedCrossRefGoogle Scholar
  20. 20.
    Heidland A, Bahner U, Vamvakas S (2000) Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis 35:347–351; discussion 52–53Google Scholar
  21. 21.
    Guba M, Graeb C, Jauch KW, Geissler EK (2004) Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77:1777–1782PubMedCrossRefGoogle Scholar
  22. 22.
    Gutierrez-Dalmau A, Campistol JM (2007) Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 67:1167–1198PubMedCrossRefGoogle Scholar
  23. 23.
    Centers for Disease Control and Prevention (2007) Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004. MMWR Morb Mortal Wkly Rep 56:161–165Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht (outside the USA) 2012

Authors and Affiliations

  • Jonathan N. Hofmann
    • 1
  • Kendra Schwartz
    • 2
    • 5
  • Wong-Ho Chow
    • 3
  • Julie J. Ruterbusch
    • 2
    • 5
  • Brian M. Shuch
    • 4
  • Sara Karami
    • 1
  • Nathaniel Rothman
    • 1
  • Sholom Wacholder
    • 6
  • Barry I. Graubard
    • 6
  • Joanne S. Colt
    • 1
  • Mark P. Purdue
    • 1
  1. 1.Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and GeneticsNational Cancer InstituteBethesdaUSA
  2. 2.Departments of Oncology and Family MedicineWayne State University, School of MedicineDetroitUSA
  3. 3.Department of EpidemiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Urologic Oncology Branch, Center for Cancer ResearchNational Cancer InstituteBethesdaUSA
  5. 5.Population Studies and Disparities Research, Karmanos Cancer InstituteDetroitUSA
  6. 6.Biostatistics Branch, Division of Cancer Epidemiology and GeneticsNational Cancer InstituteBethesdaUSA

Personalised recommendations